Fate Therapeutics Q4 2024 Earnings Report $0.92 -0.05 (-4.74%) As of 03/18/2025 04:00 PM Eastern Earnings HistoryForecast Fate Therapeutics EPS ResultsActual EPS-$0.31Consensus EPS -$0.44Beat/MissBeat by +$0.13One Year Ago EPSN/AFate Therapeutics Revenue ResultsActual Revenue$1.86 millionExpected Revenue$1.57 millionBeat/MissBeat by +$291.00 thousandYoY Revenue GrowthN/AFate Therapeutics Announcement DetailsQuarterQ4 2024Date3/5/2025TimeBefore Market OpensConference Call ResourcesFATE Earnings History Remove Ads Fate Therapeutics Earnings HeadlinesFate Therapeutics’ SWOT analysis: promising pipeline drives stock outlookMarch 14, 2025 | investing.comFate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by AnalystsMarch 13, 2025 | americanbankingnews.comYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.March 19, 2025 | American Alternative (Ad)Bank of America Securities Keeps Their Hold Rating on Fate Therapeutics (FATE)March 10, 2025 | markets.businessinsider.comFate Therapeutics price target lowered to $2.50 from $3 at BofAMarch 10, 2025 | markets.businessinsider.comQ1 EPS Estimates for Fate Therapeutics Increased by WedbushMarch 10, 2025 | americanbankingnews.comSee More Fate Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fate Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fate Therapeutics and other key companies, straight to your email. Email Address About Fate TherapeuticsFate Therapeutics (NASDAQ:FATE), a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.View Fate Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do Now Upcoming Earnings Micron Technology (3/20/2025)PDD (3/20/2025)NIKE (3/20/2025)FedEx (3/20/2025)Accenture (3/20/2025)Paychex (3/26/2025)Cintas (3/26/2025)Wells Fargo & Company (4/11/2025)Bank of New York Mellon (4/11/2025)JPMorgan Chase & Co. (4/11/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
